Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)

Next Previous
Search
Trial Profile

Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms RESPONSE
  • Sponsors Incyte Corporation; Novartis

    • Most Recent Events

    • 12 Dec 2023 Results of pooled analysis of RESPONSE and RESPONSE 2 describing patient benefit of ruxolitinib in patients with PV with or without splenomegaly,presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2022 Results of a study assessing changes of JAK2V617F variant allele fraction in PV and ET patients who were long-term treated with ruxolitinib from tow clinical studies: REPSONSE-1 and RESPONSE-2 presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 06 Nov 2019 Results demonstrating benefits and long term clinical efficacy of the ruxolitinib treatment in patients who did and did not achieve the protocol defined HCT control, released in 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top